UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$490.69 USD
-11.23 (-2.24%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $490.99 +0.30 (0.06%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth D Momentum A VGM
UnitedHealth Group (UNH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$580.00 | $675.00 | $481.00 | 15.56% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for UnitedHealth Group comes to $580.00. The forecasts range from a low of $481.00 to a high of $675.00. The average price target represents an increase of 15.56% from the last closing price of $501.92.
Analyst Price Targets (23)
Broker Rating
UnitedHealth Group currently has an average brokerage recommendation (ABR) of 1.15 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on 22 recommendations.
Of the 24 recommendations deriving the current ABR, 21 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 87.5% and 8.33% of all recommendations. A month ago, Strong Buy made up 81.82%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 21 | 19 | 18 | 18 | 18 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.15 | 1.24 | 1.25 | 1.25 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Robert W. Baird & Co. | Michael Ha | Not Available | Strong Buy |
5/1/2024 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
4/17/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
4/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
3/8/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
1/15/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
10/20/2023 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.15 |
ABR (Last week) | 1.24 |
# of Recs in ABR | 24 |
Average Target Price | $580.00 |
LT Growth Rate | 12.50% |
Industry | Medical - HMOs |
Industry Rank by ABR | 92 of 252 |
Current Quarter EPS Est: | 6.70 |